APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Monoclonal Antibodies

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Selected research

Market Structure

Global Biosimilar Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173970940321 December 2025182 pages

Choose your research edition.

Industry ResearchBiosimilar Monoclonal Antibodies Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Monoclonal Antibodies Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Biosimilar Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Monoclonal Antibodies Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Monoclonal Antibodies Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.

Read the full market overview

Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

This report provides an overview of the global Biosimilar Monoclonal Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilar Monoclonal Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilar Monoclonal Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biosimilar Monoclonal Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilar Monoclonal Antibodies Segment by Company

Celltrion

Pfizer (Hospira)

3SBIO

Novartis (Sandoz)

Dr Reddy’s

Celgen Biopharma

Cadila Healthcare

Hisun Pharma

Torrent Pharmaceuticals

Biosimilar Monoclonal Antibodies Segment by Type

Infliximab

Rituximab

Trastuzumab

Adalimumab

Other

Biosimilar Monoclonal Antibodies Segment by Application

Oncology

Autoimmune Disease

Other

Biosimilar Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilar Monoclonal Antibodies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biosimilar Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biosimilar Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biosimilar Monoclonal Antibodies Industry Trends Table 2. Biosimilar Monoclonal Antibodies Industry Drivers Table 3. Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges Table 4. Biosimilar Monoclonal Antibodies Industry Restraints Table 5. Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biosimilar Monoclonal Antibodies Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers Table 9. Global Biosimilar Monoclonal Antibodies Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Biosimilar Monoclonal Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biosimilar Monoclonal Antibodies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biosimilar Monoclonal Antibodies Manufacturers, Product Type & Application Table 13. Global Biosimilar Monoclonal Antibodies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biosimilar Monoclonal Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Infliximab Table 17. Major Manufacturers of Rituximab Table 18. Major Manufacturers of Trastuzumab Table 19. Major Manufacturers of Adalimumab Table 20. Major Manufacturers of Other Table 21. Global Biosimilar Monoclonal Antibodies Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 23. Global Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 24. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2026) Table 25. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2027-2032) Table 26. Global Biosimilar Monoclonal Antibodies Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Biosimilar Monoclonal Antibodies Revenue by Type (2021-2026) & (K Units) Table 28. Global Biosimilar Monoclonal Antibodies Revenue by Type (2027-2032) & (K Units) Table 29. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2026) Table 30. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Oncology Table 32. Major Manufacturers of Autoimmune Disease Table 33. Major Manufacturers of Other Table 34. Global Biosimilar Monoclonal Antibodies Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 36. Global Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 37. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2026) Table 38. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2027-2032) Table 39. Global Biosimilar Monoclonal Antibodies Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Biosimilar Monoclonal Antibodies Revenue by Application (2021-2026) & (K Units) Table 41. Global Biosimilar Monoclonal Antibodies Revenue by Application (2027-2032) & (K Units) Table 42. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2026) Table 43. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2027-2032) Table 44. Global Biosimilar Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2026) & (K Units) Table 46. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2021-2026) Table 47. Global Biosimilar Monoclonal Antibodies Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Biosimilar Monoclonal Antibodies Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Biosimilar Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 51. North America Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 52. Europe Biosimilar Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 54. Europe Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Biosimilar Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Biosimilar Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 61. Global Biosimilar Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Biosimilar Monoclonal Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Biosimilar Monoclonal Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2021-2026) Table 65. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2027-2032) Table 66. Celltrion Company Information Table 67. Celltrion Business Overview Table 68. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Celltrion Biosimilar Monoclonal Antibodies Product Portfolio Table 70. Celltrion Recent Development Table 71. Pfizer (Hospira) Company Information Table 72. Pfizer (Hospira) Business Overview Table 73. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio Table 75. Pfizer (Hospira) Recent Development Table 76. 3SBIO Company Information Table 77. 3SBIO Business Overview Table 78. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio Table 80. 3SBIO Recent Development Table 81. Novartis (Sandoz) Company Information Table 82. Novartis (Sandoz) Business Overview Table 83. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio Table 85. Novartis (Sandoz) Recent Development Table 86. Dr Reddy’s Company Information Table 87. Dr Reddy’s Business Overview Table 88. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio Table 90. Dr Reddy’s Recent Development Table 91. Celgen Biopharma Company Information Table 92. Celgen Biopharma Business Overview Table 93. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio Table 95. Celgen Biopharma Recent Development Table 96. Cadila Healthcare Company Information Table 97. Cadila Healthcare Business Overview Table 98. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio Table 100. Cadila Healthcare Recent Development Table 101. Hisun Pharma Company Information Table 102. Hisun Pharma Business Overview Table 103. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio Table 105. Hisun Pharma Recent Development Table 106. Torrent Pharmaceuticals Company Information Table 107. Torrent Pharmaceuticals Business Overview Table 108. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio Table 110. Torrent Pharmaceuticals Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Biosimilar Monoclonal Antibodies Distributors List Table 114. Biosimilar Monoclonal Antibodies Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Biosimilar Monoclonal Antibodies Product Image Figure 2. Global Biosimilar Monoclonal Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Monoclonal Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Monoclonal Antibodies Sales (2021-2032) & (K Units) Figure 5. Global Biosimilar Monoclonal Antibodies Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Biosimilar Monoclonal Antibodies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Infliximab Image Figure 9. Rituximab Image Figure 10. Trastuzumab Image Figure 11. Adalimumab Image Figure 12. Other Image Figure 13. Global Biosimilar Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Biosimilar Monoclonal Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2032) Figure 16. Global Biosimilar Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Biosimilar Monoclonal Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2032) Figure 19. Oncology Image Figure 20. Autoimmune Disease Image Figure 21. Other Image Figure 22. Global Biosimilar Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Biosimilar Monoclonal Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2032) Figure 25. Global Biosimilar Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Biosimilar Monoclonal Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2032) Figure 28. North America Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 30. U.S. Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 35. Germany Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 42. China Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 50. Brazil Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Biosimilar Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Biosimilar Monoclonal Antibodies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 61. North America Biosimilar Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 63. Europe Biosimilar Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Biosimilar Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Biosimilar Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Biosimilar Monoclonal Antibodies Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Biosimilar Monoclonal Antibodies Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Infliximab
  • Rituximab
  • Trastuzumab
  • Adalimumab
  • Other
Applications
  • Oncology
  • Autoimmune Disease
  • Other
Companies covered
  • Celltrion
  • Pfizer (Hospira)
  • 3SBIO
  • Novartis (Sandoz)
  • Dr Reddy’s
  • Celgen Biopharma
  • Cadila Healthcare
  • Hisun Pharma
  • Torrent Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biosimilar Monoclonal Antibodies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biosimilar Monoclonal Antibodies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biosimilar Monoclonal Antibodies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biosimilar Monoclonal Antibodies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biosimilar Monoclonal Antibodies Market Dynamics
  1. 2.1 Biosimilar Monoclonal Antibodies Industry Trends
  2. 2.2 Biosimilar Monoclonal Antibodies Industry Drivers
  3. 2.3 Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 Biosimilar Monoclonal Antibodies Industry Restraints
3 Biosimilar Monoclonal Antibodies Market by Manufacturers
  1. 3.1 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biosimilar Monoclonal Antibodies Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biosimilar Monoclonal Antibodies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biosimilar Monoclonal Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilar Monoclonal Antibodies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biosimilar Monoclonal Antibodies Manufacturers, Product Type & Application
  7. 3.7 Global Biosimilar Monoclonal Antibodies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilar Monoclonal Antibodies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilar Monoclonal Antibodies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilar Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
4 Biosimilar Monoclonal Antibodies Market by Type
  1. 4.1 Biosimilar Monoclonal Antibodies Type Introduction
  2. 4.1.1 Infliximab
  3. 4.1.2 Rituximab
  4. 4.1.3 Trastuzumab
  5. 4.1.4 Adalimumab
  6. 4.1.5 Other
  7. 4.2 Global Biosimilar Monoclonal Antibodies Sales by Type
  8. 4.2.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2032)
  10. 4.2.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2021-2032)
  11. 4.3 Global Biosimilar Monoclonal Antibodies Revenue by Type
  12. 4.3.1 Global Biosimilar Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2021-2032)
  14. 4.3.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2021-2032)
5 Biosimilar Monoclonal Antibodies Market by Application
  1. 5.1 Biosimilar Monoclonal Antibodies Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Autoimmune Disease
  4. 5.1.3 Other
  5. 5.2 Global Biosimilar Monoclonal Antibodies Sales by Application
  6. 5.2.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2032)
  8. 5.2.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2021-2032)
  9. 5.3 Global Biosimilar Monoclonal Antibodies Revenue by Application
  10. 5.3.1 Global Biosimilar Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2021-2032)
  12. 5.3.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2021-2032)
6 Global Biosimilar Monoclonal Antibodies Sales by Region
  1. 6.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2026)
  4. 6.2.2 Global Biosimilar Monoclonal Antibodies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biosimilar Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biosimilar Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biosimilar Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biosimilar Monoclonal Antibodies Revenue by Region
  1. 7.1 Global Biosimilar Monoclonal Antibodies Revenue by Region
  2. 7.1.1 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biosimilar Monoclonal Antibodies Revenue by Region (2021-2026)
  4. 7.1.3 Global Biosimilar Monoclonal Antibodies Revenue by Region (2027-2032)
  5. 7.1.4 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biosimilar Monoclonal Antibodies Revenue (2021-2032)
  8. 7.2.2 North America Biosimilar Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biosimilar Monoclonal Antibodies Revenue (2021-2032)
  11. 7.3.2 Europe Biosimilar Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biosimilar Monoclonal Antibodies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biosimilar Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biosimilar Monoclonal Antibodies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Celltrion
  2. 8.1.1 Celltrion Company Information
  3. 8.1.2 Celltrion Business Overview
  4. 8.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
  6. 8.1.5 Celltrion Recent Developments
  7. 8.2 Pfizer (Hospira)
  8. 8.2.1 Pfizer (Hospira) Company Information
  9. 8.2.2 Pfizer (Hospira) Business Overview
  10. 8.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
  12. 8.2.5 Pfizer (Hospira) Recent Developments
  13. 8.3 3SBIO
  14. 8.3.1 3SBIO Company Information
  15. 8.3.2 3SBIO Business Overview
  16. 8.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
  18. 8.3.5 3SBIO Recent Developments
  19. 8.4 Novartis (Sandoz)
  20. 8.4.1 Novartis (Sandoz) Company Information
  21. 8.4.2 Novartis (Sandoz) Business Overview
  22. 8.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
  24. 8.4.5 Novartis (Sandoz) Recent Developments
  25. 8.5 Dr Reddy’s
  26. 8.5.1 Dr Reddy’s Company Information
  27. 8.5.2 Dr Reddy’s Business Overview
  28. 8.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
  30. 8.5.5 Dr Reddy’s Recent Developments
  31. 8.6 Celgen Biopharma
  32. 8.6.1 Celgen Biopharma Company Information
  33. 8.6.2 Celgen Biopharma Business Overview
  34. 8.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
  36. 8.6.5 Celgen Biopharma Recent Developments
  37. 8.7 Cadila Healthcare
  38. 8.7.1 Cadila Healthcare Company Information
  39. 8.7.2 Cadila Healthcare Business Overview
  40. 8.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
  42. 8.7.5 Cadila Healthcare Recent Developments
  43. 8.8 Hisun Pharma
  44. 8.8.1 Hisun Pharma Company Information
  45. 8.8.2 Hisun Pharma Business Overview
  46. 8.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
  48. 8.8.5 Hisun Pharma Recent Developments
  49. 8.9 Torrent Pharmaceuticals
  50. 8.9.1 Torrent Pharmaceuticals Company Information
  51. 8.9.2 Torrent Pharmaceuticals Business Overview
  52. 8.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
  54. 8.9.5 Torrent Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biosimilar Monoclonal Antibodies Value Chain Analysis
  2. 9.1.1 Biosimilar Monoclonal Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biosimilar Monoclonal Antibodies Production Mode & Process
  6. 9.2 Biosimilar Monoclonal Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biosimilar Monoclonal Antibodies Distributors
  9. 9.2.3 Biosimilar Monoclonal Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst